Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA
By Sabela Ojea
Alnylam Pharmaceuticals said that it received a positive review from the U.S. Food and Drug Administration regarding its supplemental new drug application to treat a heart disease through its Onpattro drug.
The biopharmaceutical company said 9 out of 12 members of the cardiovascular and renal drugs Advisory committee voted that the benefits of its medication outweigh its risks for the treatment of cardiomyopathy of ATTR amyloidosis.
Transthyretin amyloid cardiomyopathy is a rare but severe cause of cardiomyopathy that takes place as a result of an accumulation of the transthyretin protein.
"We look forward to continuing to work with the FDA as they complete their review of our sNDA," said Pushkal Garg, Alnylam's chief medical officer.
Earlier on Wednesday, Alnylam Pharmaceuticals shares were halted from trading while the regulatory advisory committee met to review its sNDA.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 13, 2023 17:33 ET (21:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now